sert

Fluoxetine (LY-110140) is a highly specific serotonin uptake inhibitor and selective 5-hydroxytryptamine (5-HT) reuptake inhibitor. Fluoxetine has antidepressant activity.

Amitriptyline hydrochloride (Annoyltin) is the hydrochloride salt of the tricyclic dibenzocycloheptadiene amitriptyline with antidepressant and antinociceptive activities.

Escitalopram (Seroplex) is a furancarbonitrile that is one of the SEROTONIN UPTAKE INHIBITORS used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from tardive dyskinesia in preference to tricyclic antidepressants, which aggravate this condition.

Amitriptyline (MK-230, N-750, Ro41575) is a tricyclic antidepressant (TCA) with analgesic properties. Amitriptyline is widely used to treat depression and neuropathic pain.

Duloxetine is an inhibitor of serotonin-norepinephrine reuptake(Ki of 4.6 nM),with treatment of major depressive disorder and generalized anxiety disorder.

Azaphen (Pipofezin hydrochloride) is the reuptake of serotonin inhibitor.with antidepressant action and has sedative effects, suggesting antihistamine activity.

lumateperone Tosylate (ITI-007) is a 5-HT2A receptor antagonist (Ki: 0.54 nM), a SERT blocker (Ki: 61 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki: 32 nM).

GSK163090 is a specific and orally active 5-HT1A B D receptor antagonist (pKis: 9.4 8.5 9.7, and 6.3 6.7 for 5-HT1A B D, and dopamine D2 D3).

Dapoxetine (Dapoxetina) is a selective serotonin reuptake inhibitor, for the treatment of premature ejaculation.

Imipramine hydrochloride (Imipramine HCl) is a first generation tricyclic antidepressant that acts primarily as an inhibitor of serotonin and norepinephrine transporters (Kds = 1.4 and 37 nM, respectively).Imipramine hydrochloride is reported to prevent the translocation of aSMase, inhibiting MV and exosomes secretion

MAO-A SERT-IN-1 acts as an inhibitor for both MAO-A and the serotonin transporter (SERT). It decreases the SERT-mediated reuptake of 5-HT and demonstrates neuroprotective properties in cellular inhibition models. Additionally, this compound has shown to alleviate depressive behaviors in both zebrafish and mice.

SERT inhibitor 69419 inhibits serotonin reuptake.

RAGE SERT-IN-1 is a potent, orally active inhibitor of advanced glycation end products (RAGE) and serotonin transporter (SERT), with IC50 values of 8.26 μM and 31.09 nM, respectively. It demonstrates significant neuroprotective effects against Aβ25-35-induced neuronal damage and alleviates depressive behavior in mice. RAGE SERT-IN-1 is useful for research on the comorbidity of Alzheimer's disease and depression [1].

SERT-IN-2, a potent SERT inhibitor (IC 50 = 0.58 nM), exhibits promising efficacy as an anti-depressant. It demonstrates a favorable bioavailability of 83.28% in rats and has the ability to cross the blood-brain barrier.

SERT-IN-3 (compound 12), a serotonin transporter (SerT) inhibitor, exhibits an IC 50 value of 34.4 nM for SerT in pharmacological assays [1].

Tanzisertib (CC-930) (CC-930) is a potent inhibitor of JNK1 2 3 with IC50s of 61 7 6 nM, respectively, with potential antifibrotic activity.

Capivasertib (AZD5363) is a broad-spectrum AKT inhibitor with inhibitory activity against Akt1, Akt2, and Akt3 (IC50=3 7 7 nM) with oral activity. Capivasertib has antitumor activity for the treatment of breast cancer.

Silmitasertib (CX-4945) is a potent, orally bioavailable inhibitor of casein kinase 2 (CK2; Ki: 0.38 nM).

Galunisertib (LY2157299) is a TGF-β receptor type I (TGF-βRI) inhibitor (IC50=56 nM) that is selective. Galunisertib has antitumor activity and can be used in combination with PD-1 inhibitors.

Ceralasertib (AZD6738) is an orally active, selective ATR kinase inhibitor with an IC50 of 1 nM.

Prexasertib (LY2606368) is an inhibitor of checkpoint kinase 1 (chk1) with potential antineoplastic activity.

Elimusertib (BAY-1895344) is a potent, highly selective, and orally available ATR inhibitor with an IC50 of 7 nM, demonstrating significant anti-tumor efficacy as a monotherapy and strong combination potential with targeted alpha therapy Radium-223 dichloride.

Gartisertib (VX-803) is an orally active and selective Rad3-related protein (ATR) inhibitor with antitumor activity, inhibiting the antiproliferative effect induced in ccRCC cells, and inhibiting ATR-driven phosphorylation of checkpoint kinase 1 (Chk1), useful for studying solid tumors.

Zabedosertib (BAY 1834845) is an inhibitor of IRAK4 with immunomodulatory potential. Zabedosertib protects against acute respiratory distress syndrome, a new study suggests.